Analyze Diet
Equine veterinary journal1987; 19(4); 272-275; doi: 10.1111/j.2042-3306.1987.tb01406.x

Blood products in large animal medicine: a comparative account of current and future technology.

Abstract: THERE are indications for therapeutic uses of all portions of whole blood in large animal patients but plasma and its isolated components have the largest number of immediate applications. As recently as 10 years ago, whole fresh blood was the only routinely administered blood product. However, as even cross-match compatible erythrocytes are removed from circulation within two to four days by the reticuloendothelial system, whole blood is a poor product for expansion of vascular volume or supplying plasma components if the patient has no immediate need for increased oxygen carrying capacity. Any disease process that is amenable to plasma component therapy is necessarily also improved by the administration of whole plasma, which is more easily harvested, stored, and administered than plasma components at present. Future technology may enable us to provide concentrates of specific plasma proteins, erythrocytes, granulocytes, and platelets for focused therapy of certain disease processes.
Publication Date: 1987-07-01 PubMed ID: 3622453DOI: 10.1111/j.2042-3306.1987.tb01406.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper discusses the use of whole blood and its components in large animal medicine, noting the greater application of plasma and its components. It also looks at the shift from whole fresh blood to various blood products in veterinary medicine over the past decade, and the limitations of whole blood as a treatment. Additionally, it highlights potential advancements in future technology that may produce concentrated specific blood components for targeted therapies.

Therapeutic Uses of Blood Components in Animal Medicine

  • The paper begins by discussing the therapeutic uses of complete blood and its components in large animal medicine. While all parts of the blood can be used therapeutically, plasma and its separated components are indicated as having the widest range of immediate applications.
  • Whole fresh blood used to be the only regularly administered blood product, but this has changed within the past decade due to innovations in veterinary medicine. Now, various blood products are regularly used in treatment protocols.

Limitations of Whole Blood Therapy

  • The researchers explain the limitations of using whole blood. Even when erythrocytes (red blood cells) are cross-match compatible, they are removed from circulation within two to four days by the reticuloendothelial system (a part of the immune system). Consequently, whole blood doesn’t provide an effective solution for expanding vascular volume or supplying plasma components unless the patient requires an immediate increase in oxygen-carrying capacity.

Advantages of Plasma Therapy

  • Any disease condition that could benefit from plasma component therapy can also be improved with the administration of whole plasma. Whole plasma is beneficial because it’s more easily harvested, stored, and administered than individual plasma components in current practice.

Future Prospects in Blood Component Therapy

  • The paper also outlines potential future technological advancements that might enable the provision of specific concentrated plasma proteins, erythrocytes, granulocytes (a type of white blood cell), and platelets. These would enable focused therapy for certain disease processes, providing a targeted and potentially more effective treatment approach.

Cite This Article

APA
Morris DD. (1987). Blood products in large animal medicine: a comparative account of current and future technology. Equine Vet J, 19(4), 272-275. https://doi.org/10.1111/j.2042-3306.1987.tb01406.x

Publication

ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 19
Issue: 4
Pages: 272-275

Researcher Affiliations

Morris, D D

    MeSH Terms

    • Animals
    • Blood Transfusion / veterinary
    • Cattle
    • Cattle Diseases / blood
    • Cattle Diseases / therapy
    • Hematologic Diseases / therapy
    • Hematologic Diseases / veterinary
    • Horse Diseases / blood
    • Horse Diseases / therapy
    • Horses
    • Plasma

    Citations

    This article has been cited 2 times.
    1. Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol 2020 Mar;20(3):173-185.
      doi: 10.1038/s41577-019-0224-6pubmed: 31676858google scholar: lookup
    2. Authement JM. Preparation of components. Adv Vet Sci Comp Med 1991;36:171-85.